Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,582JPY
20 Apr 2018
Change (% chg)

¥-10 (-0.63%)
Prev Close
¥1,592
Open
¥1,594
Day's High
¥1,596
Day's Low
¥1,577
Volume
4,199,700
Avg. Vol
7,661,991
52-wk High
¥1,637
52-wk Low
¥1,332

Chart for

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.48
Market Cap(Mil.): ¥3,272,878.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.21

Financials

  4503.T Industry Sector
P/E (TTM): 17.77 31.01 33.60
EPS (TTM): 89.05 -- --
ROI: 12.20 13.60 13.19
ROE: 13.62 15.26 15.00

BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement

* PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014

8:17am EDT

BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co

* ASTELLAS ANNOUNCES SALE OF CERTAIN AGENSYS RESEARCH FACILITIES TO KITE, A GILEAD COMPANY

Apr 18 2018

BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas

* CARDURION PHARMACEUTICALS LICENSES CLINICAL STAGE HEART FAILURE CANDIDATE FROM ASTELLAS

Apr 16 2018

BRIEF- Astellas Pharma completes share repurchase

* Says it completes repurchase of 39.6 million shares of its common stock, for 60 billion yen in total, during period from Feb. 1 to March 23

Mar 25 2018

BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi

* U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

Mar 19 2018

BRIEF-Astellas Pharma acquires Universal Cells

* Says it has acquired Universal Cells Inc., and will pay up to $102.5 million of upfront and milestones to acquire 100 percent ownership of Universal Cells depending on achievement of certain specified clinical milestones

Feb 13 2018

BRIEF-Astellas acquires Universal Cells Inc

* ASTELLAS WILL PAY UP TO $102.5 MILLION OF UPFRONT AND MILESTONES TO ACQUIRE 100 PERCENT OWNERSHIP OF UNIVERSAL CELLS

Feb 13 2018

BRIEF-Astellas Pharma says top-line results for two phase 3 trials of Peficitinib in rheumatoid arthritis patients

* Says it announced that the results of two phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib hydrobromide, an oral JAK inhibitor developed by the co, in rheumatoid arthritis patients with an inadequate response to existing therapy, demonstrated superiority over placebo regarding the two trials' primary endpoints

Feb 07 2018

Pfizer's Xtandi delays prostate cancer spread in early stage disease

Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study results that could lead to significantly increased sales of the Pfizer Inc and Astellas Pharma Inc medicine.

Feb 05 2018

Pfizer's Xtandi delays prostate cancer spread in early stage disease

Feb 5 Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study results that could lead to significantly increased sales of the Pfizer Inc and Astellas Pharma Inc medicine.

Feb 05 2018

Earnings vs. Estimates